Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Human Genome Sciences Inc.
NCT07589530 · Advanced Solid Tumors, Metastatic Solid Tumors, and more
NCT07042100 · Advanced Solid Tumors
NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT07177937 · Small Cell Lung Cancer, Melanoma, and more
NCT07387068 · Advanced Solid Tumors
Stanford University Dept. of Medicine-Oncology
Stanford, California
University of Colorado Health Sciences Center
Aurora, Colorado
The Sarah Cannon Research Institute
Nashville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions